Case Control Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jan 14, 2021; 27(2): 162-175
Published online Jan 14, 2021. doi: 10.3748/wjg.v27.i2.162
Detection of fucosylated haptoglobin using the 10-7G antibody as a biomarker for evaluating endoscopic remission in ulcerative colitis
Kei Motooka, Koichi Morishita, Nami Ito, Shinichiro Shinzaki, Taku Tashiro, Satoshi Nojima, Kayoko Shimizu, Mutsuhiro Date, Natsumi Sakata, Momoko Yamada, Shinji Takamatsu, Yoshihiro Kamada, Hideki Iijima, Tsunekazu Mizushima, Eiichi Morii, Tetsuo Takehara, Eiji Miyoshi
Kei Motooka, Koichi Morishita, Nami Ito, Natsumi Sakata, Momoko Yamada, Shinji Takamatsu, Yoshihiro Kamada, Eiji Miyoshi, Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Suita 565-0871, Osaka, Japan
Shinichiro Shinzaki, Taku Tashiro, Hideki Iijima, Tetsuo Takehara, Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita 565-0871, Osaka, Japan
Satoshi Nojima, Eiichi Morii, Department of Pathology, Osaka University Graduate School of Medicine, Suita 565-0871, Osaka, Japan
Kayoko Shimizu, Mutsuhiro Date, FUJIFILM Wako Pure Chemical Corporation, Amagasaki 661-0963, Hyogo, Japan
Tsunekazu Mizushima, Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita 565-0871, Osaka, Japan
Author contributions: Miyoshi E contributed to the conception and design of the study; Motooka K, Morishita K, Ito N, Sakata N, Yamada M, Takamatsu S and Kamada Y contributed to the acquisition and analysis of data; Shimizu K and Date M produced ELISA kits and interpretation of data; Shinzaki S, Tashiro T, Nojima S, Iijima H, Mizushima T, Morii E and Takehara T provided clinical samples and data; Motooka K, Morishita K and Miyoshi E contributed to the drafting the article or revising it critically for important intellectual content; all authors approved the final version of the article.
Supported by Ministry of Education, Culture, Sports, Science and Technology of Japan, No. 19H03562; and FUJIFILM Wako Pure Chemical Corporation, No. J770701626.
Institutional review board statement: This study was approved by the ethics committee of Osaka University Hospital and conducted in accordance with approved guidelines (Approval No. 14107-10).
Informed consent statement: Written informed consent was obtained from all subjects in this study at the time of enrollment or blood sampling.
Conflict-of-interest statement: Shimizu K and Date M are employees of FUJIFILM Wako Pure Chemical Corporation and the authors received approximately $5000 per year from a collaboration grant with FUJIFILM Wako Pure Chemical Corporation. The authors declare no other conflicts of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Eiji Miyoshi, MD, PhD, Professor, Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, 1-7 Yamada-oka, Suita 565-0871, Osaka, Japan. emiyoshi@sahs.med.osaka-u.ac.jp
Received: September 23, 2020
Peer-review started: September 23, 2020
First decision: November 8, 2020
Revised: November 11, 2020
Accepted: December 23, 2020
Article in press: December 23, 2020
Published online: January 14, 2021
Core Tip

Core Tip: Fucosylation is one of the most important glycosylation involved in cancer and inflammation. Recently, we have succeeded to establish a novel glycan antibody 10-7G mAb which directly recognizes fucosylated haptoglobin (Fuc-Hpt), and developed its enzyme-linked immunosorbent assay (ELISA) system. In this study, we demonstrated the serum 10-7G values (Fuc-Hpt levels determined with 10-7G mAb ELISA) were significantly higher in patients with inflammatory bowel disease. We also found that Fuc-Hpt was produced by lymphocytes infiltrating into inflammatory sites of intestine. Moreover, statistical analyses showed that the 10-7G value could evaluate intestinal inflammation and endoscopic mucosal healing in ulcerative colitis.